ArticleCancer discovery2022
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers.
0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed
16.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 156 citations in OpenAlex.
- Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.Nature communications · 2024Trial
- Trial
- Next-generation CDK inhibitors in HR+/HER2- breast cancer.The Journal of clinical investigation · 2026Review
- Uncovering pan-cancer signatures of chemoresistance.Genome medicine · 2026Article
- CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities.Targeted oncology · 2026Review
- Article
- Cyclins and Cyclin-Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer.MedComm · 2026Review
- Article
- miR-640 Enhances Abemaciclib Sensitivity by Suppressing CDK Inhibitor Resistance-Associated Genes in Breast Cancer Cells.Journal of cellular and molecular medicine · 2026Article
- Alternative Splicing in Cyclin-Dependent Kinase 4/6 Inhibitor Resistance in Estrogen Receptor-Positive Breast Cancer.Drug development research · 2026Review
- WITHDRAWN: From CDK4/6 to CDK2 and KAT: Evolving therapeutic approaches in HR+/HER2- breast cancer.Breast (Edinburgh, Scotland) · 2026Article
- Unraveling competitive protein interactions: A critical step toward improved production and therapeutics.Journal of advanced research · 2026Review
- The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond.Nature reviews. Drug discovery · 2026Review
- Comparative analysis of distinct genomic landscapes in young-onset gBRCA1/2 breast cancer.JCI insight · 2026Article
- Article
- Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy.Cancer research · 2026Review
- Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.Nature · 2026Article
- CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis.Nature genetics · 2026Article
- PROTAC-based protein degradation: a window of opportunity for melanoma therapy.Journal of biomedical science · 2026Review
- Inhibition of CDK9 alleviates osteoarthritis by suppressing inflammation and reducing chondrocyte apoptosis.Frontiers in pharmacology · 2026Article
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 4 institutions in 3 countries.
Qing Li *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Baishan Jiang *Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-6796-9500
Jiaye Guo *Computational & Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7439-1479
Hong ShaoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Isabella S Del PrioreHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-9665-1101
Qing ChangAnti-Tumor Assessment, Memorial Sloan Kettering Cancer Center, New York, New York.
Rei KudoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-0702-5828
Zhiqiang LiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2768-5332
Pedram RazaviBreast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Bo LiuHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Andrew S BoghossianBroad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0002-7008-8138
Matthew G ReesBroad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0002-2987-7581
Melissa M RonanBroad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0003-4269-1404
Jennifer A RothBroad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0002-5117-5586
Katherine A DonovanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-8539-5106
Marta PalafoxVall d'Hebron Institute of Oncology, Barcelona, Spain.
Jorge S Reis-FilhoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Elisa de StanchinaAnti-Tumor Assessment, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-3873-315X
Eric S FischerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-7337-6306
Neal RosenProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8307-654X
Violeta SerraVall d'Hebron Institute of Oncology, Barcelona, Spain.ORCID 0000-0001-6620-1065
Andrew KoffProgram in Molecular Biology, Memorial Sloan Kettering Cancer Center, New York, New York.
John D ChoderaComputational & Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-0542-119X
Nathanael S GrayDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-5354-7403
Sarat ChandarlapatyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. chandars@mskcc.org.ORCID 0000-0003-4532-8053
Memorial Sloan Kettering Cancer Center · USBroad Institute · USHarvard University · USHebron University · PS
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTargeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI William D. Tap · 2018 to 2026
$21.5MTargeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Simon N. Powell · 2020 to 2026
$16.3MOpen data-driven infrastructure for building biomolecular force fields for predictive biophysics and drug designR01GM132386 · NIGMS · UNIVERSITY OF COLORADO · PI SHIRTS, MICHAEL R · 2020 to 2023
$3.1MDefining mechanisms of resistance to hormonal therapy in breast cancerR01CA234361 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHANDARLAPATY, SARAT, SOLIT, DAVID B. · 2019 to 2023
$2.0MThe role of reorganization energy in achieving selective kinase inhibition"R01GM121505 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI CHODERA, JOHN DAMON · 2017 to 2021
$1.8MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA217694NCI NIH HHS P50 CA247749NCI NIH HHS R01 CA234361NIGMS NIH HHS R01 GM121505NIGMS NIH HHS R01 GM132386
Abstract
Cyclin-dependent kinases 4 and 6 (CDK4/6) represent a major therapeutic vulnerability for breast cancer. The kinases are clinically targeted via ATP competitive inhibitors (CDK4/6i); however, drug resistance commonly emerges over time. To understand CDK4/6i resistance, we surveyed over 1,300 breast cancers and identified several genetic alterations (e.g.,
Indexed as
Drug Resistance, NeoplasmAntineoplastic AgentsBreast NeoplasmsCell Line, TumorCyclin-Dependent Kinase Inhibitor ProteinsFemaleHumansPiperazinesProtein Kinase InhibitorsPyridinesTumor Suppressor ProteinsAntineoplastic AgentsCyclin-Dependent Kinase Inhibitor ProteinspalbociclibPiperazinesProtein Kinase InhibitorsPyridinesTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.